Our findings support ITGB4 as a biomarker for predicting the immune subtypes and prognosis of patients with PAAD; whether ITGB4 contributes to the establishment of a cold immune microenvironment and whether targeting ITGB4 could convert cold tumors to hot tumors in PAAD warrants further investigation. This evidence concerns the gene ITGB4 and pancreatic adenocarcinoma.